152 related articles for article (PubMed ID: 20465382)
1. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
6. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
Antonarakis ES; Eisenberger MA
Nat Clin Pract Oncol; 2009 Jan; 6(1):12-3. PubMed ID: 18957947
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G; Reid AH; Yap TA; Raynaud F; Dowsett M; Settatree S; Barrett M; Parker C; Martins V; Folkerd E; Clark J; Cooper CS; Kaye SB; Dearnaley D; Lee G; de Bono JS
J Clin Oncol; 2008 Oct; 26(28):4563-71. PubMed ID: 18645193
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate for castration resistant prostate cancer.
Shah S; Ryan C
Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
[TBL] [Abstract][Full Text] [Related]
9. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
10. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
McKay RR; Werner L; Jacobus SJ; Jones A; Mostaghel EA; Marck BT; Choudhury AD; Pomerantz MM; Sweeney CJ; Slovin SF; Morris MJ; Kantoff PW; Taplin ME
Cancer; 2019 Feb; 125(4):524-532. PubMed ID: 30427533
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
[TBL] [Abstract][Full Text] [Related]
13. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.
Pezaro CJ; Mukherji D; De Bono JS
Drug Discov Today; 2012 Mar; 17(5-6):221-6. PubMed ID: 22198164
[TBL] [Abstract][Full Text] [Related]
15. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
16. [Corticotherapy in castration-resistant prostate cancer].
Lebdai S; Branchereau J; Robert G; De La Taille A; Bouchaert P
Prog Urol; 2013 Oct; 23 Suppl 1():S23-33. PubMed ID: 24314736
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer].
Omlin A; Gillessen S
Urologe A; 2012 Jan; 51(1):8-14. PubMed ID: 22258370
[TBL] [Abstract][Full Text] [Related]
18. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature.
Giacinti S; Bassanelli M; Aschelter AM; Milano A; Roberto M; Marchetti P
Anticancer Res; 2014 Nov; 34(11):6265-9. PubMed ID: 25368223
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
Ferraldeschi R; Pezaro C; Karavasilis V; de Bono J
Annu Rev Med; 2013; 64():1-13. PubMed ID: 23020876
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
